Latest Views & News

Tissue Regenix – argues “delivered robust financial and operational performance”. Has it?...

By Steve Moore | Thursday 27 January 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Describing itself as “a leading medical devices company in the field of regenerative medicine” Tissue Regenix (TRX) has made a full-year trading update headlined “Return to double digit growth in 2021” and concluding “the company has delivered robust financial and operational performance”. Why then are the shares still below 0.50p, compared to above 1.2p in May 2020?…

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

|